Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Two-Stage, Multi-Centre Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma

NCT02267213 is registered in ClinicalTrials.gov with Taiwan Liposome Company as lead sponsor.

NCT NCT02267213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02267213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Two-Stage, Multi-Centre Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma
Lead sponsor
Taiwan Liposome Company
Phase
Phase 2
Overall status
Terminated
Start date
April 10, 2014
Completion date
July 9, 2015
Enrollment
29 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma